Your browser doesn't support javascript.
loading
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones, J R; Cairns, D A; Gregory, W M; Collett, C; Pawlyn, C; Sigsworth, R; Striha, A; Henderson, R; Kaiser, M F; Jenner, M; Cook, G; Russell, N H; Williams, C; Pratt, G; Kishore, B; Lindsay, J; Drayson, M T; Davies, F E; Boyd, K D; Owen, R G; Jackson, G H; Morgan, G J.
Afiliación
  • Jones JR; The Institute of Cancer Research, London, UK.
  • Cairns DA; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Pawlyn C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Sigsworth R; The Institute of Cancer Research, London, UK.
  • Striha A; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Henderson R; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Kaiser MF; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Jenner M; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Cook G; The Institute of Cancer Research, London, UK.
  • Russell NH; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Williams C; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Pratt G; University of Leeds, Leeds, UK.
  • Kishore B; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Lindsay J; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Drayson MT; Heart of England NHS Foundation Trust, Birmingham, UK.
  • Davies FE; Heart of England NHS Foundation Trust, Birmingham, UK.
  • Boyd KD; Department of Haematology, East Kent Hospitals University NHS Foundation Trust, Kent, UK.
  • Owen RG; Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Jackson GH; The Institute of Cancer Research, London, UK.
  • Morgan GJ; The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Blood Cancer J ; 6(12): e506, 2016 12 09.
Article en En | MEDLINE | ID: mdl-27935580
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Primarias Secundarias / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Primarias Secundarias / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido